--(BUSINESS WIRE)--AN2 Therapeutics ... instrument as the primary efficacy endpoint for the Phase 3 part of the EBO-301 trial. The Company will evaluate whether the Phase 3 data supports the ...

Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapies and drugs for optical surgical navigation, announced today that it has initiated the Phase 3 portion of its ...